Available Trials
Colorectal Cancer
- Colon, RectumTemozolomide and Olaparib for O6-Methylguanine DNA Methyltransferase Promoter Hypermethylated Colorectal CancerPrincipal Investigator: Michael Cecchini
- Anus, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma, Pancreas, Prostate, Rectum, Small Intestine, Stomach, Thyroid, Phase I, Breast, Urinary BladderA Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsPrincipal Investigator: Joseph Kim
- Anus, Breast - Female, Breast - Male, Colon, Corpus Uteri, Esophagus, Hodgkin's Lymphoma, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Phase I, Unknown Sites, Breast, Cervix, Urinary BladderPhase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced CancerPrincipal Investigator: Patricia LoRusso
- Anus, Breast - Female, Breast - Male, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma, Pancreas, Prostate, Rectum, Small Intestine, Stomach, Thyroid, Phase I, Urinary BladderAn Open-Label, Phase 1, First-In-Human Study of Safety and Tolerability of TRAIL Receptor Agonist ABBV-621 in Subjects With Previously Treated Solid Tumors and Hematologic MalignanciesPrincipal Investigator: Patricia LoRusso
- Bones and Joints, Brain and Nervous System, Eye and Orbit, Hodgkin's Lymphoma, Kidney, Leukemia, other, Liver, Lymphoid Leukemia, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Small Intestine, Soft Tissue, PediatricsThe Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome StudyPrincipal Investigator: Nina Kadan-Lottick
Gastric and Esophageal
- Anus, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma, Pancreas, Prostate, Rectum, Small Intestine, Stomach, Thyroid, Phase I, Breast, Urinary BladderA Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsPrincipal Investigator: Joseph Kim
- Esophagus, Larynx, Lip, Oral Cavity and PharynxRandomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to CisplatinPrincipal Investigator: Melissa Young
- Anus, Breast - Female, Breast - Male, Colon, Corpus Uteri, Esophagus, Hodgkin's Lymphoma, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Phase I, Unknown Sites, Breast, Cervix, Urinary BladderPhase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced CancerPrincipal Investigator: Patricia LoRusso
- Anus, Breast - Female, Breast - Male, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma, Pancreas, Prostate, Rectum, Small Intestine, Stomach, Thyroid, Phase I, Urinary BladderAn Open-Label, Phase 1, First-In-Human Study of Safety and Tolerability of TRAIL Receptor Agonist ABBV-621 in Subjects With Previously Treated Solid Tumors and Hematologic MalignanciesPrincipal Investigator: Patricia LoRusso
- Bones and Joints, Brain and Nervous System, Eye and Orbit, Hodgkin's Lymphoma, Kidney, Leukemia, other, Liver, Lymphoid Leukemia, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Small Intestine, Soft Tissue, PediatricsThe Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome StudyPrincipal Investigator: Nina Kadan-Lottick
Liver Cancer
- Anus, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma, Pancreas, Prostate, Rectum, Small Intestine, Stomach, Thyroid, Phase I, Breast, Urinary BladderA Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsPrincipal Investigator: Joseph Kim
- Anus, Breast - Female, Breast - Male, Colon, Corpus Uteri, Esophagus, Hodgkin's Lymphoma, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Phase I, Unknown Sites, Breast, Cervix, Urinary BladderPhase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced CancerPrincipal Investigator: Patricia LoRusso
- Anus, Breast - Female, Breast - Male, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma, Pancreas, Prostate, Rectum, Small Intestine, Stomach, Thyroid, Phase I, Urinary BladderAn Open-Label, Phase 1, First-In-Human Study of Safety and Tolerability of TRAIL Receptor Agonist ABBV-621 in Subjects With Previously Treated Solid Tumors and Hematologic MalignanciesPrincipal Investigator: Patricia LoRusso
- Bones and Joints, Brain and Nervous System, Eye and Orbit, Hodgkin's Lymphoma, Kidney, Leukemia, other, Liver, Lymphoid Leukemia, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Small Intestine, Soft Tissue, PediatricsThe Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome StudyPrincipal Investigator: Nina Kadan-Lottick
Pancreatic Cancer
- Anus, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma, Pancreas, Prostate, Rectum, Small Intestine, Stomach, Thyroid, Phase I, Breast, Urinary BladderA Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsPrincipal Investigator: Joseph Kim
- Anus, Breast - Female, Breast - Male, Colon, Corpus Uteri, Esophagus, Hodgkin's Lymphoma, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Phase I, Unknown Sites, Breast, Cervix, Urinary BladderPhase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced CancerPrincipal Investigator: Patricia LoRusso
- Anus, Breast - Female, Breast - Male, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma, Pancreas, Prostate, Rectum, Small Intestine, Stomach, Thyroid, Phase I, Urinary BladderAn Open-Label, Phase 1, First-In-Human Study of Safety and Tolerability of TRAIL Receptor Agonist ABBV-621 in Subjects With Previously Treated Solid Tumors and Hematologic MalignanciesPrincipal Investigator: Patricia LoRusso
- Pancreas, PreventionThe Cancer of the Pancreas Screening-5 (CAPS5) StudyPrincipal Investigator: James Farrell